FDA Pulls Valneva’s Chikungunya Shot From Market Citing ‘Serious Safety Concerns’

Earlier this month, the FDA backed off on a pause in shipments of the chikungunya vaccine Ixchiq to older adults. Now, the regulator has reversed course.

Scroll to Top